Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NGLFINE

NGL FINE CHM

HealthcarePharmaceuticals & Biotechnology₹1763 cr market cap
₹2807.50 ▼ -1.44% today As of 19 Nov 2026
52-week low ₹1278.8052-week high ₹3457.80

-17.6% from the 52-week high · +122.7% above the low

NGL Fine-Chem Ltd. manufactures pharmaceuticals and intermediates for usage in veterinary and human health. The company is headquartered in Mumbai, Maharashtra and currently employs 329 full-time employees. The firm caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.

The short version. NGL FINE CHM reported revenue of ₹159 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹16 crore (up 60.0% year on year). Return on equity was 14.6% in Mar 2026. Promoter holding was 72.49% in Sep 2026, down 0.25 points over 8 quarters.

1 · The price

How has the stock traded?

NGL FINE CHM trades 17.6% below its 52-week high and 122.7% above its 52-week low.

Change over period: —

1M+2.7%
3M-6.3%
6M+18.2%
1Y+104.5%

2 · The business

Is it growing?

Sales, year on year+32.5%

Sep 2026 revenue of ₹159 cr.

Profit, year on year+60.0%

Sep 2026 net profit of ₹16 cr.

Net margin10.2%

2.2 pts higher than a year earlier.

3-year growth32.9% profit

Revenue compounded at 22.1% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1591391491281201049589
Net profit1618131610911
Net margin %10.213.29.012.38.08.90.61.4
EPS (₹)26.329.7821.8325.415.5814.960.882.07

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue501368339278318258152
Net profit4821412050578
Net margin %9.65.712.27.415.722.05.5
EPS (₹)77.934.1966.8833.1880.7791.8113.49

3 · The quality

How well does it turn capital into profit?

Return on equity was 14.6% in Mar 2026; debt to equity is 0.33.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %14.67.515.79.2
Return on capital %17.29.620.712.5
EBITDA margin %17.011.319.114.1
Net margin %9.35.611.77.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR22.1%14.2%
Profit CAGR32.9%-3.2%
Debt to equity0.33
Interest cover15.2x
Current ratio1.84
P/E ratio27.6

4 · The owners

Who holds it, and are they adding?

Promoter holding72.49%

Down 0.25 pts over 8 quarters.

Foreign institutions0.04%

Unchanged over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter72.7472.7472.7472.7472.7472.7472.4972.49-0.25
FII0.0400000.030.050.040.0
DII0000000.0200
Public27.2227.2627.2627.2627.2627.2427.4327.46+0.24

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.03% of NAV
  • Bandhan BSE Healthcare Index Fund0.03% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NGL FINE CHM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about NGL FINE CHM

What is the NGL FINE CHM share price?

NGL FINE CHM (NGLFINE) last closed at ₹2,807.50, down 1.44% on the day. Its 52-week range is ₹1,278.80 to ₹3,457.80.

What is the market cap of NGL FINE CHM?

NGL FINE CHM has a market capitalisation of about ₹1,763 crore. Its price-to-earnings ratio is 27.6.

How are NGL FINE CHM's latest results?

NGL FINE CHM reported revenue of ₹159 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹16 crore (up 60.0% year on year). Return on equity was 14.6% in Mar 2026. Promoter holding was 72.49% in Sep 2026, down 0.25 points over 8 quarters.

Who owns NGL FINE CHM?

As of Sep 2026, shareholding was: Promoter 72.49%, FII 0.04%, Public 27.46%.

How many mutual funds hold NGL FINE CHM?

2 mutual fund schemes held NGL FINE CHM in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Aug 2025 · Final Dividend - Rs. 1.75
  • 16 Aug 2024 · Final Dividend - Rs. 1.75
  • 18 Aug 2023 · Final Dividend - Rs. 1.75
  • 22 Jun 2022 · Final Dividend - Rs. 1.75
  • 12 Aug 2021 · Dividend - Rs. 1.75
  • 06 Aug 2020 · Final Dividend - Rs. 1.75

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.